Table 1

Characteristics of 14 patients with IVIG vascular complications

Patient (ref)Age/sexIVIG indicationPredisposing factorsOther treatments
A Nine patients with IVIG related MI
 Patient 1(14) 76/FUveitisHC, smokingCS, AZA, MTX
 Patient 2(12) 73/FITPHT, obesityCS
 Patient 3(12) 72/MRAHT, obesityCS
 Patient 4(17) 70/MThrombopeniaNDND
 Patient 5(16) 76/MNeuropathyHT, MIND
 Patient 61-150 60/MPolychondritisHT, CVACS
 Patient 71-150 41/FPolymyositisHT, obesityCS, AZA
 Patient 81-150 67/MNeuropathyHCCS
 Patient 91-150 67/MCytopeniaTIACS
B Six patients with IVIG related thrombotic vascular events other than MI
 Patient 10(13) 84/MNeuropathyTIAnone
 Patient 11(12) 62/FITPCVACS
 Patient 1212) 83/FITPCVACS
 Patient 1315) 62/FALSAnginaND
 Patient 14(15) 52/FNeuropathyNDND
 Patient 15(18) 27/FMyasthenia gravisMigraineCS
  • 1-150 Our present cases: HC: hypercholesterolaemia; CS: corticosteroid; AZA: azathioprine; MTX: methotrexate; ITP: immune thrombocytopenic purpura; HT: hypertension; RA: rheumatoid arthritis; ND= not determined; CVA: cerebrovascular accident; TIA: transient ischaemic attack; ALS: amyotrophic lateral sclerosis.